A federal appeals court fight over mail-order abortion pills now tests whether Biden-era rules can override state protections for women and unborn children.
Story Highlights
- Louisiana asks the court to block Food and Drug Administration mail-order abortion pill rules and restore in-person safeguards.
- A Fifth Circuit order noted Louisiana’s claims of illegal abortions and Medicaid costs tied to complications.
- The state cites a named plaintiff, Rosalie Markezich, alleging coercion with abortion pills as a key example.
- Twenty-one attorneys general and 60 lawmakers filed briefs backing Louisiana’s challenge.
Louisiana’s Case Targets 2023 Food and Drug Administration Rule Changes
Louisiana filed a lawsuit asking a federal court to declare the Food and Drug Administration’s 2023 risk rules for mifepristone unlawful, throw them out, and block mail-order access nationwide. The complaint argues the agency dropped common-sense protections when it allowed online prescribing and shipping. The state seeks both immediate and permanent court orders to reinstate in-person dispensing and restore medical oversight for women at risk. The filing spans dozens of pages and details the relief requested.
Louisiana’s attorney general said the goal is to return to pre–Biden administration safeguards that required a face-to-face visit before receiving abortion pills. Her office described the earlier rules as good common sense because doctors could confirm gestational age, screen for ectopic pregnancy, and give clear follow-up care steps. State officials also said they asked for proof of an ongoing Food and Drug Administration safety review and did not get a firm answer in public exchanges.
Appeals Court Notes State’s Evidence of Harm and Costs
The United States Court of Appeals for the Fifth Circuit issued a stay that recognized Louisiana’s documented claims while the case proceeds. The order referenced “numerous illegal abortions in Louisiana” and state Medicaid bills for women harmed by mifepristone, which the state ties to loosened federal rules. That snapshot of alleged on-the-ground harm helps explain why the court allowed interim limits while legal arguments continue on the merits of the challenge.
Louisiana’s standing rests in part on state costs for emergency care after complications. A filing at the Supreme Court by the drug manufacturer describes the Fifth Circuit’s analysis, citing about ninety-two thousand dollars in Medicaid spending tied to two women who needed emergency treatment in 2025. That figure is presented as the state’s concrete financial injury supporting its right to sue over federal policy changes.
A Named Plaintiff and Cited Cases Anchor the State’s Narrative
The lawsuit includes a private citizen, Rosalie Markezich, as a named plaintiff to show a real-world injury. Reporting on the case says she alleges a former partner obtained the drugs and coerced her to take them. The attorney general also cited six investigated cases of women harmed or “poisoned,” describing emergency complications and other risks that can be missed without in-person medical evaluation. These examples aim to show that mail-order access can invite abuse and hide danger.
A federal appeals court is weighing Louisiana’s effort to reinstate restrictions on how mifepristone, the abortion pill, can be prescribed and dispensed.
During Wednesday’s hearing, judges questioned whether Louisiana has legal standing to challenge the FDA’s 2023 decision… pic.twitter.com/oKGkalKkQt
— Just the News (@JustTheNews) September 10, 2026
Louisiana argues that telehealth prescribing and shipping abortion pills into the state undermine its pro-life laws and basic medical safeguards. The state frames the issue as both a health and rule-of-law matter: doctors should confirm key facts in person, and federal regulators should not erase safeguards that help prevent exploitation and protect unborn life. Support from 21 attorneys general and 60 lawmakers signals broader concern about the Food and Drug Administration’s recent direction on this drug.
Why This Fight Matters for States, Safety, and Separation of Powers
This dispute sits in a wider post-Dobbs legal landscape where states seek to set abortion policy while federal agencies write drug rules. Louisiana says the Food and Drug Administration’s shift to mail delivery weakens medical oversight and invites cross-border workarounds that frustrate state law. The Fifth Circuit’s engagement with Louisiana’s evidence shows courts are weighing not only access claims, but also how far an agency may go when it changes long-standing safety steps for potent drugs.
What Comes Next in the Courts
Next steps include continued briefing, potential further argument, and possible Supreme Court review as needed. While litigation moves forward, the legal standard will focus on administrative law, state standing, and what remedies are proper if the court finds the 2023 rules unlawful. One line from the record bears repeating: an arrest or allegation is not a conviction, and a claim in a filing is not yet a proven fact. The courts will decide based on the law and the evidence.
Sources:
lifesitenews.com, ca5.uscourts.gov, supremecourt.gov, guttmacher.org, wwno.org, liveaction.org
